orkambi: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358	NDA	Vertex Pharmaceuticals Incorporated	51167-122-01	56 PACKET in 1 CARTON (51167-122-01) / 1 GRANULE in 1 PACKET	2022-09-02
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358	NDA	Vertex Pharmaceuticals Incorporated	51167-500-02	56 PACKET in 1 CARTON (51167-500-02) / 1 GRANULE in 1 PACKET	2018-08-07
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358	NDA	Vertex Pharmaceuticals Incorporated	51167-900-01	56 PACKET in 1 CARTON (51167-900-01) / 1 GRANULE in 1 PACKET	2018-08-07
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038	NDA	Vertex Pharmaceuticals Incorporated	51167-700-02	4 CARTON in 1 BOX (51167-700-02) / 7 BLISTER PACK in 1 CARTON / 4 TABLET, FILM COATED in 1 BLISTER PACK	2016-09-28
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038	NDA	Vertex Pharmaceuticals Incorporated	51167-809-01	4 CARTON in 1 BOX (51167-809-01) / 7 BLISTER PACK in 1 CARTON / 4 TABLET, FILM COATED in 1 BLISTER PACK	2015-07-02
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 25, 2026

Orkambi (lumacaftor/ivacaftor) suppliers: Who manufactures, supplies, and what supply-chain IP risks matter?

Executive summary: Orkambi is supplied in the US by Vertex Pharmaceuticals Incorporated (brand owner). Manufacturing supply has historically involved Vertex’s network and contract manufacturing partners for drug product and API. Supply-chain leverage is constrained by (1) fixed formulation and manufacturing process patents tied to lumacaftor/ivacaftor combination tablets/granules and (2) Orange Book-linked IP that can raise barriers for authorized generics, 505(b)(2) combos, or ecosystem entrants attempting substitution via different manufacturing routes. Vertex controls brand, regulatory ownership, and core commercial supply channels; third-party API and excipient sourcing exists but does not reduce Vertex’s regulatory and IP lock-in for Orkambi.

Who supplies Orkambi (lumacaftor/ivacaftor) in the US and globally?

Direct brand supply: Vertex Pharmaceuticals controls US product supply for Orkambi (lumacaftor/ivacaftor), including distribution and pharmacovigilance oversight via its label obligations. In practice, physical manufacturing is performed by Vertex’s own sites and/or contract manufacturers, but the market facing supplier and label holder is Vertex.

Global supply: Orkambi commercial supply in other territories is coordinated through Vertex subsidiaries/partners and local distribution chains under country-specific regulatory authorizations. The supplier role remains with Vertex as marketing authorization holder or equivalent legal entity in each jurisdiction, while manufacturing can be handled by approved third parties tied to local regulatory submissions.

What companies manufacture lumacaftor and ivacaftor used in Orkambi?

API and intermediate sourcing: Orkambi’s active ingredients are lumacaftor and ivacaftor. The upstream API supply chain typically involves:

API manufacturers for lumacaftor and ivacaftor (separately)
Intermediate suppliers for key synthetic steps
Excipients and packaging components (tablet/granule-specific)

Supplier constraints that matter commercially:

Any manufacturer seeking to supply an authorized alternative route must clear regulatory comparability and quality system requirements for the final combination dosage form.
IP and process coverage can block substitution even if raw API is available, because the protected combination product relies on specific formulation and manufacturing processes captured in patent estates.

(Note: supplier names and plant-level details are product-registration and manufacturing disclosure dependent. Where manufacturer-specific names are not present in the publicly accessible record, they cannot be asserted without a verifiable regulatory or IP listing.)

Which manufacturing sites and contract manufacturers supply Orkambi tablets or granules?

Dosage form coverage: Orkambi is marketed as fixed-dose combination for CF (cystic fibrosis) related to F508del mutations. Depending on region and label format, Orkambi has existed in:

tablet presentations (depending on market)
granule/pack formats for pediatric dosing (region/label dependent)

Manufacturing and packaging: For a fixed-dose combination like Orkambi, supplier qualification includes:

drug product manufacturing (blend, compression or granulation, coating, tablet/granule formation)
packaging and labeling control (unit dose and child-safe packaging requirements)

Why this affects supplier strategy: Even if an alternate API vendor exists, drug product manufacturing must match the validated process and finished product specification that Vertex has submitted and licensed through regulatory filings. That ties practical supply to Vertex’s approved manufacturing network.

What does the Orange Book show about Orkambi suppliers, exclusivity, and entry barriers?

Orange Book structure: The US Orange Book lists:

active ingredients
drug products and dosage forms
approved patents and exclusivity periods (including methods and formulations for the branded product)

Supplier impact:

If Orkambi’s listed patents include formulation and manufacturing method claims, third-party supply options are constrained by the risk of infringement and the need to navigate patent challenges (505(b)(2), Paragraph IV, or other entry routes).
Even if generics can source API, infringement risk on the protected finished dosage form or protected method blocks commercial entry.

Featured snippet answer: Orange Book listing creates the legal map that defines whether any non-Vertex manufacturer can supply an approved alternative product without either (1) taking a design-around approach or (2) prevailing in patent litigation.

How many Orkambi patents cover the combination and how does that impact supplier switching?

Patent estate risk: Orkambi combination therapy typically has a multi-layer patent estate covering:

composition-of-matter for one or both actives (depending on the underlying patent families)
formulation patents for the combination and specific dosage forms
method-of-use patents (treatment regimens for CF mutation subsets)
manufacturing/process patents for producing the fixed-dose combination

Commercial supplier implication: The harder-to-design-around claims are typically the formulation and method-of-manufacture claims that map directly to the commercial dosage form. Supplier switching that attempts to change only the API vendor often fails because it does not remove infringement risk on drug product-related claims.

What generic entry risks exist for Orkambi and what does that mean for suppliers?

Entry pathways that pressure the supply chain:

Paragraph IV ANDA style challenges for immediate-release combination tablets/granules, if a route is legally and pharmaceutically feasible
505(b)(2) submissions for a “different” combination route that may still depend on the same protected product characteristics

Supplier consequence: Where the branded product has strong formulation and method coverage, generic or 505(b)(2) entrants face:

potential 180-day exclusivity contests (if they win early)
litigation and potential launch delays due to stays or settlement terms
the practical need to run commercial-scale validated manufacturing under patent and regulatory constraints

What Orkambi patent litigation affects supplier ability to replace Vertex supply?

Litigation mechanics that affect suppliers:

automatic stays tied to ANDA litigation outcomes
settlement agreements that can delay generic entry even when a challenge is filed
design-around requirements that force changes in formulation/process that upstream suppliers must then replicate

Result for suppliers: Any potential replacement supplier is not only a manufacturing problem. It is also a legal entry problem governed by the Orange Book patent list and any active litigation around Orkambi.

(Note: a supplier list is not derivable from litigation alone. Litigation identifies patent plaintiffs/defendants and parties to settlements, not the complete manufacturing vendor network.)

When does Orkambi lose exclusivity, and when can suppliers reprice or reallocate manufacturing?

Exclusivity vs patents: Two different timing gates control market freedom:

Regulatory exclusivity (prevents approval of certain alternative applications even if patent defenses exist)
Patent expirations (prevent market entry absent a successful challenge or agreement)

Supplier impact: After exclusivity ends, entrants still must overcome patent claims. Only when the last relevant Orange Book patents expire or are cleared does supply competition typically shift materially away from the brand’s approved manufacturing network.

How does Orkambi supply compare with other CFTR modulators like Symdeko and Trikafta?

Commercial substitution pressure: The CF market has moved toward newer CFTR modulator combinations. Orkambi competes with newer standards of care (for eligible mutation profiles), which can reduce total addressable demand and impact how aggressively Vertex maintains capacity.

Supplier strategy comparison:

Brand owners often preserve supply for remaining eligible indications and label cohorts.
Newer therapies can reduce growth runway for suppliers serving older combination products.

Net effect: For Orkambi, supplier relevance is tied to remaining indication coverage and the extent to which payers and clinicians still prescribe it versus alternative CFTR regimens.

Which suppliers matter most: API, formulation excipients, or packaging?

Highest leverage components:

API (lumacaftor and ivacaftor) is critical to continuity, but cannot by itself allow supply substitution of the finished product.
Drug product manufacturing and formulation controls are typically the gating factor for entry and substitution.
Packaging can matter for dosing accuracy and child-safe compliance, but is rarely the decisive IP barrier.

Business prioritization: If the goal is to map risks to alternative supply, focus on:

Vertex-approved manufacturing capability for the Orkambi finished product
formulation/process patents likely attached to the tablet/granule dosage form
any settlement or licensing pathway that permits third-party manufacturing under brand authorizations

What licensing or authorized manufacturing deals exist for Orkambi suppliers?

Authorized manufacturing: Brand owners can authorize contract manufacturing organizations to produce dosage forms under quality systems and regulatory agreements. Those agreements do not eliminate patent restrictions; they route production through sanctioned pathways.

Commercial licensing: Third parties sometimes secure supply rights via:

licensing for manufacturing under brand quality frameworks
supply agreements tied to regional regulatory needs

IP interaction: Any licensing arrangement still must avoid infringement risk, either by relying on patent expiration timing, paid license rights, or contract terms that define patent scope and compliance obligations.

Key Takeaways

Vertex is the controlling supplier entity for Orkambi as the brand owner and label regulatory responsible party; third-party manufacturing exists within Vertex’s approved supply network.
Supplier switching is constrained by Orkambi’s fixed-dose combination regulatory and patent barriers, not just API availability.
The Orange Book patent list and associated exclusivity periods define whether and when non-Vertex suppliers can commercially produce and market substitutes.
The highest-friction barriers for supply replacement are typically formulation and manufacturing/process patents tied to the finished dosage form.

FAQs

1) Are there multiple suppliers for Orkambi in the US?
Orkambi is distributed under Vertex’s brand control, while manufacturing can involve Vertex-owned and/or contract manufacturing; the relevant “supplier” depends on whether you mean label holder/distributor versus manufacturing site.

2) Can a generic supplier buy lumacaftor and ivacaftor API to make Orkambi?
API availability does not remove regulatory and patent barriers for the finished combination product, which typically includes formulation and process protections.

3) Do Orkambi formulation patents affect contract manufacturers more than API vendors?
Yes, because drug product manufacturing and formulation claims map directly to the finished dosage form that entrants must replicate under regulatory approval.

4) What is the main legal hurdle for replacing Orkambi supply?
Clearing Orange Book-listed patents and managing exclusivity and litigation-driven entry timelines.

5) How do newer CFTR modulators change Orkambi supplier demand?
They can reduce ongoing prescribing and demand for Orkambi within eligible mutation cohorts, affecting capacity planning and commercial commitment.

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/

Suppliers and packagers for orkambi

orkambi